Combinatorial chemoprevention of intestinal neoplasia
Author: ["Christopher J. Torrance","Peta E. Jackson","Elizabeth Montgomery","Kenneth W. Kinzler","Bert Vogelstein","Allan Wissner","Maria Nunes","Philip Frost","Carolyn M. Discafani"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
A combination of two drugs afforded remarkable protection from intestinal neoplasia in APCMin/+ mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APCMin/+ mice developed ∼20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.
Cite this article
Torrance, C., Jackson, P., Montgomery, E. et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6, 1024–1028 (2000). https://doi.org/10.1038/79534
